



Biology Driven Treatment Strategy for Breast Cancer

Guest Editor:

Dr. Akihiko Shimomura

Department of Breast and
Medical Oncology, National
Center for Global Health and
Medicine, Tokyo 162-8655, Japan

Deadline for manuscript
submissions:

closed (31 July 2021)

Message from the Guest Editor

Dear Colleagues,

Currently, breast cancer is classified by hormone receptor, HER2, and Ki67 status. These biomarkers are predictors of response to treatment, and treatment options such as endocrine therapy and anti-HER2 therapy are selected according to the biomarkers' expression status. However, when patients become resistant to these targeted therapies or no biomarkers are expressed, chemotherapy without specific predictors of efficacy is currently the treatment of choice. Many biomarkers such as TROP-2, HER3, PD-L1, and germline BRCA1/2 mutations have been developed, and targeted therapies for each biomarker have been applied in the clinical setting. Optimal breast cancer treatment using these biomarkers will be discussed.

Dr. Akihiko Shimomura

Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer
Institute, Winston-Salem, NC
27103, USA
2. Division of Hematologic
Malignancies and Cellular
Therapy, Duke University,
Durham, NC 27710, USA

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, ‘omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank: JCR - Q2 (*Medicine, General & Internal*) CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Journal of Personalized Medicine
Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/jpm
jpm@mdpi.com
[X@JPM_MDPI](https://twitter.com/JPM_MDPI)